MRI can identify metastatic bladder cancer patients who will not respond to chemotherapy after just two treatment cycles, according to a study from The Netherlands. Chemotherapy represents the only ...

Patients with an aggressive form of bladder cancer could receive treatment in nearly half the time if a cheaper, less-invasive test is used, research has found. Researchers from the University of ...

Giving patients with suspected bladder cancer an MRI scan before surgery could mean they would be treated more quickly, leading to fewer deaths due to the disease, new research suggests. The findings, ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney ...

Prognostic role of programmed cell death protein 1 expression in surgically treated patients with upper tract urothelial carcinoma. Long-term effects of Bacilles Calmette-Guerin perfusion therapy for ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Use of multiparametric MRI for the initial staging of suspected MIBC shortened the time to correct treatment compared with TURBT. Incorporating multiparametric MRI (mpMRI) into the initial staging of ...

Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.

PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed ...